Katie Hopkins

Dr. Katie Hopkins

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in Journal of Microbiological Methods
Verified
Journal Article
Closed access
ACAlessandra Carattoli
Alessandra Carattoli
ABAlessia Bertini
Alessia Bertini
LVLaura Villa
Laura Villa
VFVincenzo Falbo
Vincenzo Falbo
KHKatie Hopkins
Katie Hopkins
ETE. John Threlfall
E. John Threlfall

1 February 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
HGHajo Grundmann
Hajo Grundmann
CGCorinna Glasner
Corinna Glasner
BABarbara Albiger
Barbara Albiger
DADavid M Aanensen
David M Aanensen
CTChris T Tomlinson
Chris T Tomlinson
DBDerek J. Brown
Derek J. Brown

1 January 2017 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
MEM.J. Ellington
M.J. Ellington
OEO. Ekelund
O. Ekelund
FAFrank Møller Aarestrup
Frank Møller Aarestrup
RCR. Canton
R. Canton
MDM. Doumith
M. Doumith
NWN. Woodford
N. Woodford

1 May 2005 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
KHKatie Hopkins
Katie Hopkins
RDRobert H. Davies
Robert H. Davies
ETE. John Threlfall
E. John Threlfall

4 April 2016 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
SESarah G. Earle
Sarah G. Earle
CWChieh-Hsi Wu
Chieh-Hsi Wu
JCJane Charlesworth
Jane Charlesworth
NSNicole Stoesser
Nicole Stoesser
NGN. Claire Gordon
N. Claire Gordon
DWDaniel J. Wilson
Daniel J. Wilson

29 August 2018 in mSphere
Verified
Journal Article
Open access
PDF file
LRLouise Roer
Louise Roer
SOSøren Overballe-Petersen
Søren Overballe-Petersen
FHFrank Hansen
Frank Hansen
KSKristian Schønning
Kristian Schønning
MWMikala Wang
Mikala Wang
HHHenrik Hasman
Henrik Hasman
Escherichia coli sequence type 410 (ST410) has been reported worldwide as an extraintestinal pathogen associated with resistance to fluoroquinolones, third-generation cephalosporins, and carbapenems. In the present study, we investigated national epidemiology of ST410 E. coli isolates from Danish patients. Furthermore, E. coli ST410 was investigated in a global context to provide further insight into the acquisition of the carbapenemase genes blaOXA-181 and blaNDM-5 of this successful lineage. From 127 whole-genome-sequenced isolates, we reconstructed an evolutionary framework of E. coli ST410 which portrays the antimicrobial-resistant clades B2/H24R, B3/H24Rx, and B4/H24RxC. The B2/H24R and B3/H24Rx clades emerged around 1987, concurrently with the C1/H30R and C2/H30Rx clades in E. coli ST131. B3/H24Rx appears to have evolved by the acquisition of the extended-spectrum β-lactamase (ESBL)-encoding gene blaCTX-M-15 and an IncFII plasmid, encoding IncFIA and IncFIB. Around 2003, the carbapenem-resistant clade B4/H24RxC emerged when ST410 acquired an IncX3 plasmid carrying a blaOXA-181 carbapenemase gene. Around 2014, the clade B4/H24RxC acquired a second carbapenemase gene, blaNDM-5, on a conserved IncFII plasmid. From an epidemiological investigation of 49 E. coli ST410 isolates from Danish patients, we identified five possible regional outbreaks, of which one outbreak involved nine patients with blaOXA-181- and blaNDM-5-carrying B4/H24RxC isolates. The accumulated multidrug resistance in E. coli ST410 over the past two decades, together with its proven potential of transmission between patients, poses a high risk in clinical settings, and thus, E. coli ST410 should be considered a lineage with emerging “high-risk” clones, which should be monitored closely in the future. IMPORTANCE Extraintestinal pathogenic Escherichia coli (ExPEC) is the main cause of urinary tract infections and septicemia. Significant attention has been given to the ExPEC sequence type ST131, which has been categorized as a “high-risk” clone. High-risk clones are globally distributed clones associated with various antimicrobial resistance determinants, ease of transmission, persistence in hosts, and effective transmission between hosts. The high-risk clones have enhanced pathogenicity and cause severe and/or recurrent infections. We show that clones of the E. coli ST410 lineage persist and/or cause recurrent infections in humans, including bloodstream infections. We found evidence of ST410 being a highly resistant globally distributed lineage, capable of patient-to-patient transmission causing hospital outbreaks. Our analysis suggests that the ST410 lineage should be classified with the potential to cause new high-risk clones. Thus, with the clonal expansion over the past decades and increased antimicrobial resistance to last-resort treatment options, ST410 needs to be monitored prospectively.